Firms invested in the tech stalwarts, including ValueAct and Lone Pine, have earned gains from these stocks that have helped ease losses from Valeant Pharmaceuticals.
O. Andreas Halvorsen, Viking Global Investors (Bloomberg) The past few weeks have not been easy for hedge funds, but many of them have tech stocks to thank for keeping the damage under control. While several
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.